Despite the recent progress in the broad‐scaled analysis of proteins in body fluids, there is
still a lack in protein profiling approaches for biomarkers of rare diseases. Scarcity of …

Serum biomarkers in Duchenne muscular dystrophy (DMD) may provide deeper insights
into disease pathogenesis, suggest new therapeutic approaches, serve as acute read-outs …

The optimization of large-scale screening procedures of pathological specimens by
genomic, proteomic and metabolic methods has drastically increased the bioanalytical …

Background X-linked muscular dystrophy is a primary disease of the neuromuscular system.
Primary abnormalities in the Dmd gene result in the absence of the full-length isoform of the …

Representatives of academia, patient organisations, industry and the United States Food
and Drug Administration attended a workshop on dystrophin quantification methodology …

Duchenne muscular dystrophy (DMD) is a genetic muscle wasting condition with limited
treatment options available and is caused by the lack of dystrophin. However …

Purpose To identify and validate serum biomarkers for the progression of D uchenne
muscular dystrophy (DMD) using a MS‐based bottom‐up pipeline. Experimental design We …

Purpose Duchenne muscular dystrophy (DMD) is a severe and fatal neuromuscular disease.
With the current developments on novel therapeutic strategies for DMD, the need to carefully …

In skeletal muscle, the dystrophin-glycoprotein complex forms a membrane-associated
assembly of relatively low abundance, making its detailed proteomic characterization in …

Background: Duchenne Muscular Dystrophy is a severe, incurable disorder caused by
mutations in the dystrophin gene. The disease is characterized by decreased muscle …